ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Down 19.1% in September

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the recipient of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 111,200 shares, a decrease of 19.1% from the August 31st total of 137,500 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average daily trading volume, of 74,200 shares, the short-interest ratio is currently 1.5 days.

ABVC BioPharma Stock Up 4.1 %

Shares of NASDAQ ABVC opened at $0.69 on Friday. ABVC BioPharma has a 52 week low of $0.60 and a 52 week high of $3.35. The business’s 50 day moving average price is $0.70 and its 200 day moving average price is $0.90. The firm has a market cap of $7.46 million, a P/E ratio of -0.31 and a beta of 0.81.

ABVC BioPharma (NASDAQ:ABVC) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.09) EPS for the quarter. ABVC BioPharma had a negative return on equity of 139.97% and a negative net margin of 8,363.97%. The company had revenue of $0.12 million during the quarter.

Institutional Investors Weigh In On ABVC BioPharma

A hedge fund recently bought a new stake in ABVC BioPharma stock. Chase Investment Counsel Corp acquired a new position in ABVC BioPharma, Inc. (NASDAQ:ABVC) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 178,377 shares of the company’s stock, valued at approximately $233,000. Chase Investment Counsel Corp owned approximately 1.69% of ABVC BioPharma at the end of the most recent quarter. Hedge funds and other institutional investors own 11.38% of the company’s stock.

About ABVC BioPharma

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.